Varicella zoster immune globulin Disease Interactions

Thrombotic events may occur during or after treatment with varicella zoster immune globulin. At-risk patients include those with history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization, and/or known/suspected hyperviscosity. Baseline assessment of blood viscosity should be considered in patients at risk for hyperviscosity (including patients with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols [triglycerides], or monoclonal gammopathies). Varicella zoster immune globulin should be administered IM only. In patients with severe thrombocytopenia or any coagulation disorder that would contraindicate IM injections, varicella zoster immune globulin should be administered only if the expected benefits outweigh the potential risks.